Small molecule target for suppression of autoimmunity in rheumatoid arthritis

抑制类风湿性关节炎自身免疫的小分子靶点

• 批准号: 7326950
• 负责人: Scott McNear Thacher
• 金额: $ 25.82万
• 依托单位: ORPHAGEN PHARMACEUTICALS
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-01 至 2008-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7326950
• 关键词: Adverse effects; Affect; Affinity; Agonist; American; Animal Model; Animals; Autoimmune Diseases; Autoimmunity; Behavior; Bioavailable; Biological Assay; CD4 Positive T Lymphocytes; Cell Differentiation process; Cell physiology; Cells; Class; Collagen; Collagen Arthritis; Collagen Type II; Crohn' s disease; Development; Disease; Dose; Drug Delivery Systems; Drug Design; Drug Kinetics; Evaluation; Family; Genetic; Genetic Transcription; Goals; Grant; Helper-Inducer T-Lymphocyte; Immune; Immune system; Immunization; In Vitro; Inflammation; Inflammatory; Interleukin-17; Investigation; Joints; Knockout Mice; Knowledge; Laboratories; Lead; Ligands; Link; Measures; Mediating; Metabolic; Methotrexate; Modeling; Modification; Multiple Sclerosis; Mus; Nuclear; Nuclear Orphan Receptor; Onset of illness; Orphan; Pain; Pathogenesis; Patients; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmacology; Phase; Positioning Attribute; Predisposition; Property; Public Health; Resistance; Retinoids; Rheumatoid Arthritis; Role; Safety; Sampling; Severities; Severity of illness; Small Business Funding Mechanisms; Small Business Innovation Research Grant; Specificity; Steroids; Surrogate Endpoint; Symptoms; T-Lymphocyte; Testing; Th1 Cells; Therapeutic; Thyroid Gland; Time; Toxic effect; Transfection; Upper arm; Week; analog; autoreactive T cell; base; cell type; cytokine; day; drug mechanism; drug metabolism; human data; human study; immune function; improved; in vivo; infliximab; inhibitor/antagonist; interleukin-23; knockout animal; lymph nodes; novel; receptor; research study; response; small molecule; transcription factor

DESCRIPTION (provided by applicant): The pro-inflammatory cytokine IL-17 has been implicated in joint destruction and in the inflammatory pathogenesis of rheumatoid arthritis (RA) in human studies. Targeted deletion or inhibition of IL-17 leads to significant reduction in disease severity in animal models of RA. A recently discovered lineage of CD4+ T cells, functionally distinct from the better known CD4+ T helper cells Th1 and Th2, expresses IL-17 and is referred to as Th-17. IL-23 is a survival factor for Th-17 cells. Since IL-23 knockout animals are resistant to induction of RA, Th-17 cells are potentially of major importance in the pathogenesis of the disease. The applicants have identified small molecule ligands to an orphan receptor that is required for the formation of Th-17 cells and have shown that receptor antagonists block Th-17 differentiation from na¿ve CD4+ T cells. In this study, we propose to evaluate the utility of this novel receptor as a drug target for RA by identifying lead compounds with good pharmacokinetic properties for testing in murine collagen-induced arthritis (CIA), an established animal model of RA. Current receptor antagonists are not suitable for definitive in vivo studies. The specific aims of this investigation will include: (1) synthesis of analogs to promising drug-like hits with a medicinal chemistry partner in order to increase potency and improve metabolic stability for in vivo testing; (2) identification of the major IL-17+ T cell types induced in CIA draining lymph nodes and characterization of their response to receptor ligands; and (3) evaluation of lead compound effects in CIA both during disease induction and from the time of first symptoms, about day 30, in order to better understand the mechanism of drug effect. The toxicity and secondary immune effects of this new compound class will be investigated as well. Our goal is to create an entirely new class of orally-bioavailable drugs for RA that blocks the major T cell-mediated arm of immune pathogenesis in the disease, thereby providing an efficacious therapy with reduced side effects and broader therapeutic utility in comparison to steroids, methotrexate and other small molecule drugs routinely used for treatment of RA. With regard to relevance to public health, rheumatoid arthritis (RA) is a painful and crippling disease that affects two million Americans. New drugs that target the immune system (such as entanercept and infliximab) have provided relief for some but not all patients, but the drugs also have serious side effects that may limit their use. The proposed studies would take the first step to develop a new class of small molecule, orally-bioavailable drugs designed to inhibit the function of a novel, potentially pathogenic immune cell that recent scientific evidence strongly suggests is involved in the pathogenesis of RA.

描述（由申请人提供）：在人类研究中，促炎细胞因子IL-17与关节破坏和类风湿关节炎（RA）的炎症发病机制有关。靶向缺失或抑制IL-17可显著降低RA动物模型的疾病严重程度。最近发现的一种CD4+ T细胞谱系，在功能上不同于众所周知的CD4+ T辅助细胞Th1和Th2，表达IL-17，被称为Th-17。IL-23是Th-17细胞的存活因子。由于IL-23敲除动物对RA的诱导具有抗性，因此Th-17细胞在RA的发病机制中可能具有重要意义。申请人已经确定了一种孤儿受体的小分子配体，这种受体是形成Th-17细胞所必需的，并且已经证明受体拮抗剂可以阻止Th-17从无CD4+ T细胞分化。在这项研究中，我们建议通过鉴定具有良好药代动力学特性的先导化合物，在小鼠胶原诱导关节炎（CIA）中进行测试，以评估这种新型受体作为RA药物靶点的效用，CIA是一种已建立的RA动物模型。目前的受体拮抗剂不适合明确的体内研究。本研究的具体目的包括：(1)与药物化学合作伙伴合成有前途的药物类似物，以提高体内测试的效力和改善代谢稳定性；(2) CIA引流淋巴结诱导的主要IL-17+ T细胞类型的鉴定及其对受体配体的反应；(3)评估CIA中铅化合物在疾病诱发期间和首次出现症状时（约30天）的作用，以便更好地了解药物作用机制。并对这类化合物的毒性和次生免疫效应进行了研究。我们的目标是创造一种全新的口服生物可利用药物，用于治疗RA，阻断疾病中主要的T细胞介导的免疫发病机制，从而提供一种有效的治疗方法，与类固醇、甲氨蝶呤和其他常规用于治疗RA的小分子药物相比，副作用更小，治疗效果更广泛。就公共健康而言，类风湿性关节炎（RA）是一种痛苦和致残的疾病，影响着200万美国人。针对免疫系统的新药（如entanepept和英夫利昔单抗）已经为一些但不是所有的患者提供了缓解，但这些药物也有严重的副作用，可能会限制它们的使用。拟议的研究将迈出第一步，开发一类新的小分子，口服生物可利用药物，旨在抑制一种新的，潜在的致病性免疫细胞的功能，最近的科学证据强烈表明，这种免疫细胞与RA的发病机制有关。